{"DataElement":{"publicId":"7595448","version":"1","preferredName":"Intratumoral or Peritumoral Lymphocytic Disease Response Outcome","preferredDefinition":"The disease status or response to treatment of intratumoral or peritumoral lymphocytes.","longName":"RS_RSORRES_LYMPRESP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"7050244","version":"1","preferredName":"Disease Response Domain Intratumoral Or Peritumoral Lymphocytic Disease Response","preferredDefinition":"A domain for disease response evaluations._Within a tumor._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Located in tissues surrounding a tumor._Of or pertaining to lymphocytes._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"6608777v1.0:7050242v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6608777","version":"1","preferredName":"Disease Response Domain","preferredDefinition":"A domain for disease response evaluations.","longName":"C107097","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Response Domain","conceptCode":"C107097","definition":"A domain for disease response evaluations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6DD03A-0CB9-71AE-E053-F662850AB42C","latestVersionIndicator":"Yes","beginDate":"2019-01-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-14","modifiedBy":"ONEDATA","dateModified":"2019-01-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7050242","version":"1","preferredName":"Intratumoral Or Peritumoral Lymphocytic Disease Response","preferredDefinition":"Within a tumor.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:Located in tissues surrounding a tumor.:Of or pertaining to lymphocytes.:The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"7050242v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intratumoral","conceptCode":"C28036","definition":"Within a tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Peritumoral","conceptCode":"C119010","definition":"Located in tissues surrounding a tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lymphocytic","conceptCode":"C13350","definition":"Of or pertaining to lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96DE8CF9-E919-4F86-E053-F662850AF404","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-11-08","modifiedBy":"ONEDATA","dateModified":"2019-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"96DE8CF9-E92A-4F86-E053-F662850AF404","latestVersionIndicator":"Yes","beginDate":"2019-11-08","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-11-08","modifiedBy":"KUMMEROA","dateModified":"2020-06-18","changeDescription":"Released. AK 2020-6-10; Created for CDSIC aligned NCI Standard CRFs. ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6674536","version":"1.2","preferredName":"CDISC SDTM Tumor Response Result Terminology Outcome","preferredDefinition":"Terminology associated with the tumor response result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM)._The result of an action.","longName":"ONCRSR","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"EQUIVOCAL","valueDescription":"Equivocal","ValueMeaning":{"publicId":"5178198","version":"1","preferredName":"Equivocal","longName":"5178198","preferredDefinition":"Open to question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Equivocal","conceptCode":"C86071","definition":"Open to question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E58EB10-C86C-1000-E050-BB89AD43077B","latestVersionIndicator":"Yes","beginDate":"2016-03-18","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-03-18","modifiedBy":"COOPERM","dateModified":"2018-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7A94-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"FAVORABLE RESPONSE","valueDescription":"Favorable Response","ValueMeaning":{"publicId":"6674538","version":"1","preferredName":"Favorable Response","longName":"6674538","preferredDefinition":"No new lesions(s) and a decrease in tumor size, or a reduction in central necrosis or attenuation in one or more enhancing lesions, based on pre-defined thresholds.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Favorable Response","conceptCode":"C123584","definition":"No new lesions(s) and a decrease in tumor size, or a reduction in central necrosis or attenuation in one or more enhancing lesions, based on pre-defined thresholds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83E8FF08-DF7C-1D09-E053-F662850ACD4A","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7A95-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"DISEASE TRANSFORMATION","valueDescription":"Disease Transformation","ValueMeaning":{"publicId":"6674539","version":"1","preferredName":"Disease Transformation","longName":"6674539","preferredDefinition":"A conversion from one disease diagnosis to another, which may be considered a progression to a worsening state.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Transformation","conceptCode":"C123583","definition":"A conversion from one disease diagnosis to another, which may be considered a progression to a worsening state.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83E8FF08-DFA9-1D09-E053-F662850ACD4A","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7A96-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"CYTOGENETIC PR","valueDescription":"Cytogenetic Partial Response","ValueMeaning":{"publicId":"5508166","version":"1","preferredName":"Cytogenetic Partial Response","longName":"5508166","preferredDefinition":"A partial decrease in abnormal karyotype, based on pre-defined thresholds.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Partial Response","conceptCode":"C123582","definition":"A partial decrease in abnormal karyotype, based on pre-defined thresholds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E4A5C62-66ED-5C40-E053-F662850A331B","latestVersionIndicator":"Yes","beginDate":"2016-10-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7A97-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"CYTOGENETIC NO RESPONSE","valueDescription":"Cytogenetic No Response","ValueMeaning":{"publicId":"5508170","version":"1","preferredName":"Cytogenetic No Response","longName":"5508170","preferredDefinition":"No change in abnormal karyotype, based on pre-defined thresholds.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic No Response","conceptCode":"C123581","definition":"No change in abnormal karyotype, based on pre-defined thresholds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E4A5C62-6739-5C40-E053-F662850A331B","latestVersionIndicator":"Yes","beginDate":"2016-10-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7A98-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"CYTOGENETIC MINOR RESPONSE","valueDescription":"Cytogenetic Minor Response","ValueMeaning":{"publicId":"5508168","version":"1","preferredName":"Cytogenetic Minor Response","longName":"5508168","preferredDefinition":"A minor decrease in abnormal karyotype, based on pre-defined thresholds.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Minor Response","conceptCode":"C123580","definition":"A minor decrease in abnormal karyotype, based on pre-defined thresholds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E4A5C62-6713-5C40-E053-F662850A331B","latestVersionIndicator":"Yes","beginDate":"2016-10-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7A99-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"CYTOGENETIC MINIMAL RESPONSE","valueDescription":"Cytogenetic Minimal Response","ValueMeaning":{"publicId":"5508158","version":"1","preferredName":"Cytogenetic Minimal Response","longName":"5508158","preferredDefinition":"A minimal decrease in abnormal karyotype, based on pre-defined thresholds.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Minimal Response","conceptCode":"C123579","definition":"A minimal decrease in abnormal karyotype, based on pre-defined thresholds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E4A5C62-6655-5C40-E053-F662850A331B","latestVersionIndicator":"Yes","beginDate":"2016-10-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7A9A-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"CYTOGENETIC CR","valueDescription":"Cytogenetic Complete Response","ValueMeaning":{"publicId":"5508164","version":"1","preferredName":"Cytogenetic Complete Response","longName":"5508164","preferredDefinition":"The disappearance of all signs of cancer, including the absence of a detectable disease-related genetic abnormality, as determined by techniques such as karyotyping or FISH, in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Complete Response","conceptCode":"C123578","definition":"The disappearance of all signs of cancer, including the absence of a detectable disease-related genetic abnormality, as determined by techniques such as karyotyping or FISH, in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E4A5C62-66C7-5C40-E053-F662850A331B","latestVersionIndicator":"Yes","beginDate":"2016-10-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7A9B-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"CRi","valueDescription":"Complete Response with Incomplete Bone Marrow Recovery","ValueMeaning":{"publicId":"6674540","version":"1","preferredName":"Complete Response with Incomplete Bone Marrow Recovery","longName":"6674540","preferredDefinition":"The disappearance of all signs of cancer in response to treatment accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Response with Incomplete Bone Marrow Recovery","conceptCode":"C103385","definition":"The disappearance of all signs of cancer in response to treatment accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83E8FF08-E035-1D09-E053-F662850ACD4A","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"MMADDINENI","dateModified":"2023-09-13","changeDescription":null,"administrativeNotes":"2023.3.22 Alt VM added per ticket request CADSR0002191. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7A9C-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"CR-CT","valueDescription":"Complete Response by Computed Tomography","ValueMeaning":{"publicId":"6674542","version":"1","preferredName":"Complete Response by Computed Tomography","longName":"6674542","preferredDefinition":"The disappearance of all signs of cancer, based on CT scan and criteria-defined assessments.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Response by Computed Tomography","conceptCode":"C123577","definition":"The disappearance of all signs of cancer, based on CT scan and criteria-defined assessments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83E8FF08-E05B-1D09-E053-F662850ACD4A","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7A9D-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"CR","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3854972","version":"1","preferredName":"Complete Remission","longName":"3854972","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86FD-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7A9E-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"cPR","valueDescription":"Clinical Partial Response","ValueMeaning":{"publicId":"6674544","version":"1","preferredName":"Clinical Partial Response","longName":"6674544v1.00","preferredDefinition":"A decrease in the size and the extent of tissue involvement by cancer, based on physical exam, such as palpation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Partial Response","conceptCode":"C123576","definition":"A decrease in the size and the extent of tissue involvement by cancer, based on physical exam, such as palpation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83E8FF08-E08C-1D09-E053-F662850ACD4A","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"MMADDINENI","dateModified":"2023-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7A9F-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"CMR","valueDescription":"Tumor Complete Metabolic Response","ValueMeaning":{"publicId":"6674548","version":"1","preferredName":"Tumor Complete Metabolic Response","longName":"6674548","preferredDefinition":"A finding of disappearance of metabolic tumor activity in target and non-target lesions, marked by a decrease in tumor standardized uptake value to the level of surrounding normal tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Complete Metabolic Response","conceptCode":"C123407","definition":"A finding of disappearance of metabolic tumor activity in target and non-target lesions, marked by a decrease in tumor standardized uptake value to the level of surrounding normal tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83E8FF08-E0D8-1D09-E053-F662850ACD4A","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AA1-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"CHR","valueDescription":"Complete Hematologic Response","ValueMeaning":{"publicId":"5540398","version":"1","preferredName":"Complete Hematologic Response","longName":"5540398","preferredDefinition":"The disappearance of cancer in response to treatment, including platelet and white blood cell counts returning to normal levels, a non-palpable spleen, and no immature white blood cells present in the blood unless it is a regenerating marrow following treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Hematologic Response","conceptCode":"C123575","definition":"The disappearance of cancer in response to treatment, including platelet and white blood cell counts returning to normal levels, a non-palpable spleen, and no immature white blood cells present in the blood unless it is a regenerating marrow following treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FA1F895-F1B8-05B5-E053-F662850AA504","latestVersionIndicator":"Yes","beginDate":"2016-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AA2-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"cCR","valueDescription":"Clinical Complete Response","ValueMeaning":{"publicId":"5838504","version":"1","preferredName":"Clinical Complete Response","longName":"5838504","preferredDefinition":"The disappearance of all signs of cancer based on physical exam, such as palpation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Complete Response","conceptCode":"C123574","definition":"The disappearance of all signs of cancer based on physical exam, such as palpation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"506DC049-356A-7059-E053-F662850A6D2C","latestVersionIndicator":"Yes","beginDate":"2017-05-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-05-26","modifiedBy":"CLOHNES","dateModified":"2023-11-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AA3-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"CA125 75% RESPONSE","valueDescription":"CA125 75% Response","ValueMeaning":{"publicId":"6674550","version":"1","preferredName":"CA125 75% Response","longName":"6674550","preferredDefinition":"The amount of cancer antigen 125 is reduced by 75% from protocol-defined baseline value(s).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CA125 75% Response","conceptCode":"C123573","definition":"The amount of cancer antigen 125 is reduced by 75% from protocol-defined baseline value(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83E8FF08-E11E-1D09-E053-F662850ACD4A","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AA4-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"CA125 50% RESPONSE","valueDescription":"CA125 50% Response","ValueMeaning":{"publicId":"6674552","version":"1","preferredName":"CA125 50% Response","longName":"6674552","preferredDefinition":"The amount of cancer antigen 125 is reduced by 50% from protocol-defined baseline value(s).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CA125 50% Response","conceptCode":"C123572","definition":"The amount of cancer antigen 125 is reduced by 50% from protocol-defined baseline value(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83E8FF08-E144-1D09-E053-F662850ACD4A","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AA5-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"ABSENT MORPHOLOGIC RESPONSE","valueDescription":"Absent Morphologic Response","ValueMeaning":{"publicId":"6674554","version":"1","preferredName":"Absent Morphologic Response","longName":"6674554","preferredDefinition":"The absence of change in the overall attenuation of the metastasis and in the peripheral rim, suggesting a lack of response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Absent Morphologic Response","conceptCode":"C123571","definition":"The absence of change in the overall attenuation of the metastasis and in the peripheral rim, suggesting a lack of response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83E8FF08-E16A-1D09-E053-F662850ACD4A","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AA6-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"pCR","valueDescription":"Pathologic Complete Response","ValueMeaning":{"publicId":"6674595","version":"1","preferredName":"Pathologic Complete Response","longName":"6674595","preferredDefinition":"The disappearance of all signs of cancer, supported by pathological examination.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic Complete Response","conceptCode":"C123603","definition":"The disappearance of all signs of cancer, supported by pathological examination.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EAD60C-2126-4346-E053-F662850AE7A9","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AA7-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"PARTIAL MORPHOLOGIC RESPONSE","valueDescription":"Partial Morphologic Response","ValueMeaning":{"publicId":"6674597","version":"1","preferredName":"Partial Morphologic Response","longName":"6674597","preferredDefinition":"Mixed attenuation and some homogeneity of the metastases with a partially resolved peripheral rim.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Morphologic Response","conceptCode":"C123602","definition":"Mixed attenuation and some homogeneity of the metastases with a partially resolved peripheral rim.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EAD60C-214C-4346-E053-F662850AE7A9","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AA8-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"OPTIMAL MORPHOLOGIC RESPONSE","valueDescription":"Optimal Morphologic Response","ValueMeaning":{"publicId":"6674599","version":"1","preferredName":"Optimal Morphologic Response","longName":"6674599","preferredDefinition":"Hypo-attenuation of the metastases which may appear pseudocystic, perfectly homogeneous, and devoid of a recognizable peripheral rim.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Optimal Morphologic Response","conceptCode":"C123601","definition":"Hypo-attenuation of the metastases which may appear pseudocystic, perfectly homogeneous, and devoid of a recognizable peripheral rim.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EAD60C-2172-4346-E053-F662850AE7A9","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AA9-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"NR","valueDescription":"No Response","ValueMeaning":{"publicId":"5654573","version":"1","preferredName":"No Response","longName":"5654573","preferredDefinition":"No apparent change or worsening in tumor staging classification.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No Response","conceptCode":"C123600","definition":"No apparent change or worsening in lesion staging classification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E126E3-C3C0-533A-E053-F662850A36AA","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AAA-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"NOT ALL EVALUATED","valueDescription":"Not All Lesions Evaluated","ValueMeaning":{"publicId":"4273169","version":"1","preferredName":"Not All Lesions Evaluated","longName":"4273169","preferredDefinition":"Not all target lesions were assessed. Or not all non-target lesions were assessed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not All Lesions Evaluated","conceptCode":"C103424","definition":"Not all target lesions were assessed. Or not all non-target lesions were assessed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F72DFE87-DE58-5FDE-E040-BB89AD433D0A","latestVersionIndicator":"Yes","beginDate":"2014-04-16","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2014-04-16","modifiedBy":"COOPERM","dateModified":"2020-04-27","changeDescription":"Updated Long Name and Definition to match current NCIt. mc 4/27/2020","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AAB-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"NON-QUANTIFIABLE MRD POSITIVITY","valueDescription":"Non-Quantifiable Minimal Residual Disease Positivity","ValueMeaning":{"publicId":"6674601","version":"1","preferredName":"Non-Quantifiable Minimal Residual Disease Positivity","longName":"6674601","preferredDefinition":"Presence of non-quantifiable residual disease based on laboratory techniques.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Quantifiable Measurable Residual Disease Positivity","conceptCode":"C124431","definition":"Presence of non-quantifiable residual disease based on laboratory techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EAD60C-21D7-4346-E053-F662850AE7A9","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AAC-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"NON-PD","valueDescription":"Non Progressive Disease","ValueMeaning":{"publicId":"5946381","version":"1","preferredName":"Non Progressive Disease","longName":"5946381","preferredDefinition":"Following a previous assessment of progressive disease unconfirmed (PDu) of non-target lesion(s), the subsequent required assessment does not confirm progressive disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non Progressive Disease","conceptCode":"C123599","definition":"Following a previous assessment of progressive disease unconfirmed (PDu) of non-target lesion(s), the subsequent required assessment does not confirm progressive disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58007ED1-2129-70C3-E053-F662850A7199","latestVersionIndicator":"Yes","beginDate":"2017-08-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AAD-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"NON-iCR/NON-iUPD","valueDescription":"Non iRECIST Complete Response-Non iRECIST Unconfirmed Progressive Disease","ValueMeaning":{"publicId":"6059613","version":"1","preferredName":"Non iRECIST Complete Response-Non iRECIST Unconfirmed Progressive Disease","longName":"6059613","preferredDefinition":"Persistence of one or more non-target lesion(s) without unequivocal progression following an initial apparent radiographic progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non iRECIST Complete Response-Non iRECIST Unconfirmed Progressive Disease","conceptCode":"C142361","definition":"Persistence of one or more non-target lesion(s) without unequivocal progression following an initial apparent radiographic progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"642A8BA4-5722-6C04-E053-F662850A1959","latestVersionIndicator":"Yes","beginDate":"2018-02-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-02-01","modifiedBy":"ONEDATA","dateModified":"2018-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AAE-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"NON-CR/NON-PD","valueDescription":"Non Complete Response/Non Progressive Disease","ValueMeaning":{"publicId":"5946383","version":"1","preferredName":"Non Complete Response/Non Progressive Disease","longName":"5946383v1.00","preferredDefinition":"Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker levels above the normal limits. (RECIST)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non Complete Response/Non Progressive Disease","conceptCode":"C96700","definition":"Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker levels above the normal limits. (RECIST)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58007ED1-215D-70C3-E053-F662850A7199","latestVersionIndicator":"Yes","beginDate":"2017-08-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-30","modifiedBy":"MMADDINENI","dateModified":"2022-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AAF-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"NED","valueDescription":"No Evidence of Disease","ValueMeaning":{"publicId":"2559523","version":"1","preferredName":"No Evidence of Disease","longName":"2559523","preferredDefinition":"Diagnostic tests fail to detect presence of disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No Evidence of Disease","conceptCode":"C40413","definition":"Diagnostic tests fail to detect presence of disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B590-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AB0-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"NE","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3855538","version":"1","preferredName":"Unevaluable","longName":"3855538","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3F3FD8B-328D-C859-E040-BB89AD43580F","latestVersionIndicator":"Yes","beginDate":"2013-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AB1-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"MRD RELAPSE","valueDescription":"Minimal Residual Disease Relapse","ValueMeaning":{"publicId":"6674603","version":"1","preferredName":"Minimal Residual Disease Relapse","longName":"6674603","preferredDefinition":"Presence of residual disease based on pre-defined thresholds and return of quantifiable MRD positivity after a period of MRD negativity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Measurable Residual Disease Relapse","conceptCode":"C124430","definition":"Presence of residual disease based on pre-defined thresholds and return of quantifiable MRD positivity after a period of MRD negativity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EAD60C-2252-4346-E053-F662850AE7A9","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AB2-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"MR","valueDescription":"Minor Response","ValueMeaning":{"publicId":"5607583","version":"1","preferredName":"Minor Response","longName":"5607583","preferredDefinition":"A finding indicating that there is an improvement in the measures of disease burden, meeting a predetermined threshold, but not meeting partial response criteria.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minimal Response","conceptCode":"C123598","definition":"A finding indicating that there is an improvement in the measures of disease burden, meeting a predetermined threshold, but not meeting partial response criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"44053298-D162-7592-E053-F662850AB82F","latestVersionIndicator":"Yes","beginDate":"2016-12-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-19","modifiedBy":"SOKKERL","dateModified":"2023-09-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AB5-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"MORPHOLOGIC LEUKEMIA-FREE STATE","valueDescription":"Morphologic Leukemia - Free State","ValueMeaning":{"publicId":"2581112","version":"1","preferredName":"Morphologic Leukemia - Free State","longName":"2581112","preferredDefinition":"The disappearance of all cells with morphologic characteristics of leukemia, accompanied by bone marrow recovery, in response to treatment. Hematologic recovery is not required. Leukemia free state can be a hypocellular marrow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Leukemia-Free State","conceptCode":"C123597","definition":"The disappearance of all cells with morphologic characteristics of leukemia, accompanied by bone marrow recovery, in response to treatment. Hematologic recovery is not required. Leukemia free state can be a hypocellular marrow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-09E5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-10-02","modifiedBy":"COOPERM","dateModified":"2018-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AB6-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"MORPHOLOGIC CRi","valueDescription":"Morphologic Complete Remission with Incomplete Blood Count Recovery ","ValueMeaning":{"publicId":"3854971","version":"1","preferredName":"Morphologic Complete Remission with Incomplete Blood Count Recovery ","longName":"3854971","preferredDefinition":"The disappearance of all cells with morphologic characteristics of cancer, accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Complete Remission with Incomplete Blood Count Recovery","conceptCode":"C123596","definition":"The disappearance of all cells with morphologic characteristics of cancer, accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86DA-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AB7-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"MORPHOLOGIC CR","valueDescription":"Morphologic Complete Response","ValueMeaning":{"publicId":"5634991","version":"1","preferredName":"Morphologic Complete Response","longName":"5634991","preferredDefinition":"The disappearance of all signs of cancer, supported by morphological analysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Complete Response","conceptCode":"C123595","definition":"The disappearance of all signs of cancer, supported by morphological analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"471517FD-CEBD-70F2-E053-F662850AF62D","latestVersionIndicator":"Yes","beginDate":"2017-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AB8-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"MOLECULAR MAJOR RESPONSE","valueDescription":"Molecular Major Response","ValueMeaning":{"publicId":"5508162","version":"1","preferredName":"Molecular Major Response","longName":"5508162","preferredDefinition":"A decrease in signs of cancer, supported by molecular analysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Molecular Major Response","conceptCode":"C123594","definition":"A decrease in signs of cancer, supported by molecular analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E4A5C62-66A1-5C40-E053-F662850A331B","latestVersionIndicator":"Yes","beginDate":"2016-10-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AB9-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"MOLECULAR CR","valueDescription":"Molecular Complete Response","ValueMeaning":{"publicId":"5508160","version":"1","preferredName":"Molecular Complete Response","longName":"5508160","preferredDefinition":"The disappearance of all signs of cancer, supported by molecular analysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Molecular Complete Response","conceptCode":"C123593","definition":"The disappearance of all signs of cancer, supported by molecular analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E4A5C62-667B-5C40-E053-F662850A331B","latestVersionIndicator":"Yes","beginDate":"2016-10-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ABA-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"MINOR PATHOLOGIC RESPONSE","valueDescription":"Minor Pathologic Response","ValueMeaning":{"publicId":"6674607","version":"1","preferredName":"Minor Pathologic Response","longName":"6674607","preferredDefinition":"A minor decrease in signs of cancer, supported by pathological examination and based on pre-defined thresholds.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minor Pathologic Response","conceptCode":"C123592","definition":"A minor decrease in signs of cancer, supported by pathological examination and based on pre-defined thresholds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EAD60C-2331-4346-E053-F662850AE7A9","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ABB-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"mCR","valueDescription":"Marrow Complete Response","ValueMeaning":{"publicId":"6301234","version":"1","preferredName":"Marrow Complete Response","longName":"6301234","preferredDefinition":"A decrease in the number of bone marrow plasma cells to protocol-defined level(s).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Marrow Complete Response","conceptCode":"C123591","definition":"A decrease in the number of bone marrow plasma cells to protocol-defined level(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CEA4F9D-74F9-32DD-E053-F662850AE25B","latestVersionIndicator":"Yes","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ABC-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"MAJOR PATHOLOGIC RESPONSE","valueDescription":"Major Pathologic Response","ValueMeaning":{"publicId":"6674609","version":"1","preferredName":"Major Pathologic Response","longName":"6674609","preferredDefinition":"A major decrease in signs of cancer, supported by pathological examination and based on pre-defined thresholds.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Major Pathologic Response","conceptCode":"C123590","definition":"A major decrease in signs of cancer, supported by pathological examination and based on pre-defined thresholds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EAD60C-236C-4346-E053-F662850AE7A9","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ABD-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"iUPD","valueDescription":"iRECIST Unconfirmed Progressive Disease","ValueMeaning":{"publicId":"6056543","version":"1","preferredName":"iRECIST Unconfirmed Progressive Disease","longName":"6056543","preferredDefinition":"Apparent radiographic progression which requires confirmation, per criteria, with additional imaging.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"iRECIST Unconfirmed Progressive Disease","conceptCode":"C142360","definition":"Apparent radiographic progression which requires confirmation, per criteria, with additional imaging.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"639DB17C-5ACC-166C-E053-F662850A2137","latestVersionIndicator":"Yes","beginDate":"2018-01-25","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-25","modifiedBy":"ONEDATA","dateModified":"2018-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ABE-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"iSD","valueDescription":"iRECIST Stable Disease","ValueMeaning":{"publicId":"6056539","version":"1","preferredName":"iRECIST Stable Disease","longName":"6056539","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity based on predetermined boundaries following an initial apparent radiographic progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"iRECIST Stable Disease","conceptCode":"C142359","definition":"Cancer that is neither decreasing nor increasing in extent or severity based on predetermined boundaries following an initial apparent radiographic progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"639DB17C-5A80-166C-E053-F662850A2137","latestVersionIndicator":"Yes","beginDate":"2018-01-25","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-25","modifiedBy":"ONEDATA","dateModified":"2018-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ABF-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"iPR","valueDescription":"iRECIST Partial Response","ValueMeaning":{"publicId":"6056541","version":"1","preferredName":"iRECIST Partial Response","longName":"6056541","preferredDefinition":"A finding indicating that there is a decrease based on a predetermined threshold in the size and the extent of tissue involvement by cancer following an initial apparent radiographic progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"iRECIST Partial Response","conceptCode":"C142358","definition":"A finding indicating that there is a decrease based on a predetermined threshold in the size and the extent of tissue involvement by cancer following an initial apparent radiographic progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"639DB17C-5AA6-166C-E053-F662850A2137","latestVersionIndicator":"Yes","beginDate":"2018-01-25","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-25","modifiedBy":"ONEDATA","dateModified":"2018-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AC0-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"INDETERMINATE RESPONSE","valueDescription":"Indeterminate Response","ValueMeaning":{"publicId":"6272413","version":"1","preferredName":"Indeterminate Response","longName":"6272413","preferredDefinition":"A response that is neither favorable nor unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indeterminate Response","conceptCode":"C123589","definition":"A response that is neither favorable nor unfavorable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BDB14F5-C3AF-40C4-E053-F662850AE75B","latestVersionIndicator":"Yes","beginDate":"2018-05-10","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-10","modifiedBy":"SOKKERL","dateModified":"2018-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AC1-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"IMMUNOPHENOTYPIC CR","valueDescription":"Immunophenotypic Complete Response","ValueMeaning":{"publicId":"6674611","version":"1","preferredName":"Immunophenotypic Complete Response","longName":"6674611","preferredDefinition":"The disappearance of all signs of cancer, supported by the absence of phenotypically aberrant plasma cells (clonal) in bone marrow. (Rajkumar SV, Harousseau J, Durie B et al, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117(18):4691-4695)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunophenotypic Complete Response","conceptCode":"C123588","definition":"The disappearance of all signs of cancer, supported by the absence of phenotypically aberrant plasma cells (clonal) in bone marrow. (Rajkumar SV, Harousseau J, Durie B et al, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117(18):4691-4695)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EAD60C-23C8-4346-E053-F662850AE7A9","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AC2-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"iCR","valueDescription":"iRECIST Complete Response","ValueMeaning":{"publicId":"6056547","version":"1","preferredName":"iRECIST Complete Response","longName":"6056547","preferredDefinition":"The disappearance of all signs of cancer following an initial apparent radiographic progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"iRECIST Complete Response","conceptCode":"C142357","definition":"The disappearance of all signs of cancer following an initial apparent radiographic progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"639DB17C-5B18-166C-E053-F662850A2137","latestVersionIndicator":"Yes","beginDate":"2018-01-25","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-25","modifiedBy":"ONEDATA","dateModified":"2018-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AC3-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"iCPD","valueDescription":"iRECIST Confirmed Progressive Disease","ValueMeaning":{"publicId":"6056545","version":"1","preferredName":"iRECIST Confirmed Progressive Disease","longName":"6056545","preferredDefinition":"Radiographic progression which has been confirmed by additional imaging showing worsening of initial progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"iRECIST Confirmed Progressive Disease","conceptCode":"C142356","definition":"Radiographic progression which has been confirmed by additional imaging showing worsening of initial progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"639DB17C-5AF2-166C-E053-F662850A2137","latestVersionIndicator":"Yes","beginDate":"2018-01-25","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-01-25","modifiedBy":"ONEDATA","dateModified":"2018-01-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AC4-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"HI-P","valueDescription":"Hematologic Improvement-Platelet Response","ValueMeaning":{"publicId":"6301232","version":"1","preferredName":"Hematologic Improvement-Platelet Response","longName":"6301232","preferredDefinition":"An improvement of platelet count as a response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic Improvement-Platelet Response","conceptCode":"C123587","definition":"An improvement of platelet count as a response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CEA4F9D-74CF-32DD-E053-F662850AE25B","latestVersionIndicator":"Yes","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AC5-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"HI-N","valueDescription":"Hematologic Improvement-Neutrophil Response","ValueMeaning":{"publicId":"6301230","version":"1","preferredName":"Hematologic Improvement-Neutrophil Response","longName":"6301230","preferredDefinition":"An improvement of neutrophil count as a response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic Improvement-Neutrophil Response","conceptCode":"C123586","definition":"An improvement of neutrophil count as a response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CEA4F9D-74A5-32DD-E053-F662850AE25B","latestVersionIndicator":"Yes","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AC6-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"HI-E","valueDescription":"Hematologic Improvement-Erythroid Response","ValueMeaning":{"publicId":"6301228","version":"1","preferredName":"Hematologic Improvement-Erythroid Response","longName":"6301228","preferredDefinition":"An improvement in erythrocyte count as a response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic Improvement-Erythroid Response","conceptCode":"C123585","definition":"An improvement in erythrocyte count as a response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CEA4F9D-747B-32DD-E053-F662850AE25B","latestVersionIndicator":"Yes","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AC7-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"VGPR","valueDescription":"Very good Partial Response","ValueMeaning":{"publicId":"3669391","version":"1","preferredName":"Very good Partial Response","longName":"3669391","preferredDefinition":"Partial response with additional serum and urine M-protein reduction, but not meeting complete response.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Very Good Partial Response","conceptCode":"C123618","definition":"Partial response with additional serum and urine M-protein reduction, but not meeting complete response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D4813252-CCB5-71BE-E040-BB89AD4341ED","latestVersionIndicator":"Yes","beginDate":"2013-01-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Added concept annotation. mc 4/11/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AC8-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"UNFAVORABLE RESPONSE","valueDescription":"Unfavorable Response","ValueMeaning":{"publicId":"6674613","version":"1","preferredName":"Unfavorable Response","longName":"6674613","preferredDefinition":"An increase in tumor size, based on a pre-defined threshold, or the development of new lesion(s), marked central fill-in of a lesion, or new enhancement of a previously homogeneously hypoattenuating nonenhancing mass.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unfavorable Response","conceptCode":"C123617","definition":"An increase in tumor size, based on a pre-defined threshold, or the development of new lesion(s), marked central fill-in of a lesion, or new enhancement of a previously homogeneously hypoattenuating nonenhancing mass.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EC8B42-FF69-3D97-E053-F662850A1D83","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AC9-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"UNEQUIVOCAL","valueDescription":"Unequivocal","ValueMeaning":{"publicId":"6034928","version":"1","preferredName":"Unequivocal","longName":"6034928","preferredDefinition":"Leaving no doubt; not open to question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unequivocal","conceptCode":"C123645","definition":"Leaving no doubt; not open to question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F28737C-D723-2FA7-E053-F662850A0C69","latestVersionIndicator":"Yes","beginDate":"2017-11-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-11-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ACA-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"TREATMENT FAILURE","valueDescription":"Lack of Efficacy","ValueMeaning":{"publicId":"2578570","version":"1","preferredName":"Lack of Efficacy","longName":"2578570","preferredDefinition":"The lack of expected or desired effect related to a therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lack of Efficacy","conceptCode":"C48226","definition":"The lack of expected or desired effect related to a therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FFF7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-22","changeDescription":null,"administrativeNotes":"2023.3.22 Alt VM added per ticket request CADSR0002191. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ACB-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"SMD","valueDescription":"Stable Metabolic Disease","ValueMeaning":{"publicId":"6674615","version":"1","preferredName":"Stable Metabolic Disease","longName":"6674615","preferredDefinition":"The absence of change or mild changes of metabolic tumor activity in all relevant lesions based on a pre-defined threshold.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Metabolic Disease","conceptCode":"C123616","definition":"The absence of change or mild changes of metabolic tumor activity in all relevant lesions based on a pre-defined threshold.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EC8B42-FFAD-3D97-E053-F662850A1D83","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ACC-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"SD-CT","valueDescription":"Stable Disease by Computed Tomography","ValueMeaning":{"publicId":"6674617","version":"1","preferredName":"Stable Disease by Computed Tomography","longName":"6674617","preferredDefinition":"The size and extent of tissue involvement by cancer is neither decreasing nor increasing, based on CT scan and criteria-defined assessments.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease by Computed Tomography","conceptCode":"C123615","definition":"The size and extent of tissue involvement by cancer is neither decreasing nor increasing, based on CT scan and criteria-defined assessments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EC8B42-FFD3-3D97-E053-F662850A1D83","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ACD-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"SD","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2982985","version":"1","preferredName":"Stable Disease","longName":"2982985","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-0176-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ACE-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"sCR","valueDescription":"Stringent Complete Response","ValueMeaning":{"publicId":"2955995","version":"1","preferredName":"Stringent Complete Response","longName":"2955995","preferredDefinition":"The confirmed disappearance of all signs of cancer, and absence of molecular or cytogenetic marker of disease, in response to treatment with additional biochemical, immunological and histopathological analyses to verify the CR.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stringent Complete Response","conceptCode":"C123614","definition":"The confirmed disappearance of all signs of cancer, and absence of molecular or cytogenetic marker of disease, in response to treatment with additional biochemical, immunological and histopathological analyses to verify the CR.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76D78551-E906-AA5D-E040-BB89AD435A4F","latestVersionIndicator":"Yes","beginDate":"2009-10-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2009-10-26","modifiedBy":"MAESKEB","dateModified":"2020-08-12","changeDescription":"Added concept annotation and changed case of Long Name. mc 4/11/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ACF-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"RELAPSED DISEASE FROM CR OR PR","valueDescription":"Relapsed Disease From Complete or Partial Response","ValueMeaning":{"publicId":"6674619","version":"1","preferredName":"Relapsed Disease From Complete or Partial Response","longName":"6674619","preferredDefinition":"The return of a disease after a period of complete remission or partial remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relapsed Disease From Complete or Partial Response","conceptCode":"C123613","definition":"The return of a disease after a period of complete remission or partial remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EC8B43-000F-3D97-E053-F662850A1D83","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AD0-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"RELAPSED DISEASE FROM CR","valueDescription":"Relapsed Disease From Complete Response","ValueMeaning":{"publicId":"6674621","version":"1","preferredName":"Relapsed Disease From Complete Response","longName":"6674621","preferredDefinition":"The return of a disease after a period of complete remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relapsed Disease From Complete Response","conceptCode":"C123612","definition":"The return of a disease after a period of complete remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EC8B43-0035-3D97-E053-F662850A1D83","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AD1-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"RELAPSED DISEASE","valueDescription":"Recurrent Disease","ValueMeaning":{"publicId":"3828963","version":"1","preferredName":"Recurrent Disease","longName":"3828963","preferredDefinition":"The return of a disease after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2A8BB67-2BCE-B6D0-E040-BB89AD43093C","latestVersionIndicator":"Yes","beginDate":"2013-07-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-29","modifiedBy":"SOKKERL","dateModified":"2023-12-04","changeDescription":null,"administrativeNotes":"2023.1.20 Alt VM added per ticket request CADSR0001943. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AD2-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"QUANTIFIABLE MRD POSITIVITY","valueDescription":"Quantifiable Minimal Residual Disease Positivity","ValueMeaning":{"publicId":"6452644","version":"1","preferredName":"Quantifiable Minimal Residual Disease Positivity","longName":"6452644","preferredDefinition":"Presence of quantifiable residual disease based on laboratory techniques.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Quantifiable Measurable Residual Disease Positivity","conceptCode":"C124432","definition":"Presence of quantifiable residual disease based on laboratory techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"772C74EB-93ED-6421-E053-F662850AB8BE","latestVersionIndicator":"Yes","beginDate":"2018-10-01","endDate":null,"createdBy":"COLBERTM","dateCreated":"2018-10-01","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AD3-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"PSA PROGRESSION","valueDescription":"PSA Progression","ValueMeaning":{"publicId":"5497872","version":"1","preferredName":"PSA Progression","longName":"5497872","preferredDefinition":"The amount of prostate specific antigen is increased, based on pre-defined thresholds.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PSA Progression","conceptCode":"C123611","definition":"The amount of prostate specific antigen is increased, based on pre-defined thresholds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3DF9392D-FAA3-2D20-E053-F662850A402F","latestVersionIndicator":"Yes","beginDate":"2016-10-03","endDate":null,"createdBy":"COLBERTM","dateCreated":"2016-10-03","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AD4-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"PR-CT","valueDescription":"Partial Response by Computed Tomography","ValueMeaning":{"publicId":"6674623","version":"1","preferredName":"Partial Response by Computed Tomography","longName":"6674623","preferredDefinition":"A decrease in the size and extent of tissue involvement by cancer, based on CT scan and criteria-defined assessments.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Response by Computed Tomography","conceptCode":"C123610","definition":"A decrease in the size and extent of tissue involvement by cancer, based on CT scan and criteria-defined assessments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EC8B43-0099-3D97-E053-F662850A1D83","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AD5-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"PR WITH LYMPHOCYTOSIS","valueDescription":"Partial Response with Lymphocytosis","ValueMeaning":{"publicId":"6674625","version":"1","preferredName":"Partial Response with Lymphocytosis","longName":"6674625","preferredDefinition":"A decrease in the size and extent of tissue involvement by cancer, accompanied by an increase in blood lymphocyte count above a predetermined threshold.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Response with Lymphocytosis","conceptCode":"C128998","definition":"A decrease in the size and extent of tissue involvement by cancer, accompanied by an increase in blood lymphocyte count above a predetermined threshold.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EC8B43-00BF-3D97-E053-F662850A1D83","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AD6-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"PR","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"3951935","version":"1","preferredName":"Partial Remission","longName":"3951935","preferredDefinition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB155E17-C5B7-CEC3-E040-BB89AD4342C2","latestVersionIndicator":"Yes","beginDate":"2013-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AD7-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"PMR","valueDescription":"Partial Metabolic Response","ValueMeaning":{"publicId":"6674627","version":"1","preferredName":"Partial Metabolic Response","longName":"6674627","preferredDefinition":"A decrease of metabolic tumor activity in all relevant lesions, based on a pre-defined threshold.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Metabolic Response","conceptCode":"C123609","definition":"A decrease of metabolic tumor activity in all relevant lesions, based on a pre-defined threshold.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EC8B43-00F0-3D97-E053-F662850A1D83","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AD8-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"PMD","valueDescription":"Progressive Metabolic Disease","ValueMeaning":{"publicId":"6260516","version":"1","preferredName":"Progressive Metabolic Disease","longName":"6260516","preferredDefinition":"An increase of metabolic tumor activity in all relevant lesions, based on pre-defined thresholds, or the development of new lesions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Metabolic Disease","conceptCode":"C123608","definition":"An increase of metabolic tumor activity in all relevant lesions, based on pre-defined thresholds, or the development of new lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B3F48C6-2BB7-271A-E053-F662850ACD44","latestVersionIndicator":"Yes","beginDate":"2018-05-03","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AD9-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"PDu","valueDescription":"Unconfirmed Progressive Disease","ValueMeaning":{"publicId":"5895900","version":"1","preferredName":"Unconfirmed Progressive Disease","longName":"5895900","preferredDefinition":"A disease process that is increasing in scope or severity but the criteria for progressive disease is not met.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unconfirmed Progressive Disease","conceptCode":"C123607","definition":"A disease process that is increasing in scope or severity but the criteria for progressive disease is not met.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"53BAF5DA-713C-75C8-E053-F662850AED93","latestVersionIndicator":"Yes","beginDate":"2017-07-07","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-07-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ADA-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"PD/RELAPSE AFTER HI","valueDescription":"Progression or Relapse After Hematologic Improvement","ValueMeaning":{"publicId":"6674629","version":"1","preferredName":"Progression or Relapse After Hematologic Improvement","longName":"6674629","preferredDefinition":"Disease progression or the return of a disease after a period of remission, occurring after a hematologic improvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progression or Relapse After Hematologic Improvement","conceptCode":"C123605","definition":"Disease progression or the return of a disease after a period of remission, occurring after a hematologic improvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EC8B43-0140-3D97-E053-F662850A1D83","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ADB-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"PD-CT","valueDescription":"Progressive Disease by Computed Tomography","ValueMeaning":{"publicId":"6674631","version":"1","preferredName":"Progressive Disease by Computed Tomography","longName":"6674631","preferredDefinition":"There is an increase in the size and extent of tissue involvement by cancer, based on CT scan and criteria-defined assessments.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease by Computed Tomography","conceptCode":"C123606","definition":"There is an increase in the size and extent of tissue involvement by cancer, based on CT scan and criteria-defined assessments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EC8B43-0166-3D97-E053-F662850A1D83","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ADC-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"PD FROM PR","valueDescription":"Progression from Partial Response","ValueMeaning":{"publicId":"6674633","version":"1","preferredName":"Progression from Partial Response","longName":"6674633","preferredDefinition":"Disease progression occurring after a partial response.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progression from Partial Response","conceptCode":"C123604","definition":"Disease progression occurring after a partial response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EC8B43-018C-3D97-E053-F662850A1D83","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ADD-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"PD","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"3284666","version":"1","preferredName":"Progressive Disease","longName":"3284666v1.00","preferredDefinition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD9FC7D6-531D-BE97-E040-BB89AD437875","latestVersionIndicator":"Yes","beginDate":"2011-09-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-23","modifiedBy":"MMADDINENI","dateModified":"2024-02-22","changeDescription":null,"administrativeNotes":"2023.5.17 Alt VM added per ticket request CADSR0002435. ak \r\n2023.3.15 Per LS at COG Protocol defined progressive disease (should have been added as a VM Alt Name for PV 3284666). ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ADE-75F8-E053-731AD00A4F34","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE","valueDescription":"No Steroid Use Beyond Physiologic Replacement Dose","ValueMeaning":{"publicId":"6859123","version":"1","preferredName":"No Steroid Use Beyond Physiologic Replacement Dose","longName":"6859123","preferredDefinition":"An indication that the subject's steroid dose is the same as their physiologic replacement dose.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No Steroid Use Beyond Physiologic Replacement Dose","conceptCode":"C161412","definition":"An indication that the subject's steroid dose is the same as their physiologic replacement dose.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"90A1CF7F-747A-10D6-E053-F662850AE9C6","latestVersionIndicator":"Yes","beginDate":"2019-08-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-08-21","modifiedBy":"ONEDATA","dateModified":"2019-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7ADF-75F8-E053-731AD00A4F34","beginDate":"2019-08-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"PSEUDORESPONSE","valueDescription":"Pseudoresponse","ValueMeaning":{"publicId":"5608378","version":"1","preferredName":"Pseudoresponse","longName":"5608378","preferredDefinition":"A marked decrease in contrast enhancement that is not due to actual tumor shrinkage, but that may be due to anti-angiogenic therapy or an increase in steroid dosage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pseudoresponse","conceptCode":"C131142","definition":"A marked decrease in contrast enhancement that is not due to actual tumor shrinkage, but that may be due to anti-angiogenic therapy or an increase in steroid dosage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"441B5856-09BA-6675-E053-F662850A5A59","latestVersionIndicator":"Yes","beginDate":"2016-12-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-20","modifiedBy":"SOKKERL","dateModified":"2023-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AE0-75F8-E053-731AD00A4F34","beginDate":"2019-08-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"IMPROVED","valueDescription":"Improved","ValueMeaning":{"publicId":"5118334","version":"1","preferredName":"Improved","longName":"5118334","preferredDefinition":"A subjective response indicating that something improved.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Improved","conceptCode":"C125459","definition":"A subjective response indicating that something improved.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2AE01DED-1B7B-CC47-E050-BB89AD4354E0","latestVersionIndicator":"Yes","beginDate":"2016-02-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-02-03","modifiedBy":"TAYLORT","dateModified":"2020-04-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AE1-75F8-E053-731AD00A4F34","beginDate":"2019-08-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"PSEUDOPROGRESSION","valueDescription":"Pseudoprogression","ValueMeaning":{"publicId":"3294017","version":"1","preferredName":"Pseudoprogression","longName":"3294017","preferredDefinition":"A radiologic finding observed during magnetic resonance imaging of brain glioblastoma, following concurrent radiotherapy and temozolomide treatment or vaccine therapy. It refers to the false positive finding of progression and enhancement of the lesion. It is considered a treatment effect due to tumor cell necrosis and subsequent edema formation and increased vascular permeability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pseudoprogression","conceptCode":"C98298","definition":"A radiologic finding observed during magnetic resonance imaging of brain glioblastoma, following concurrent radiotherapy and temozolomide treatment or vaccine therapy. It refers to the false positive finding of progression and enhancement of the lesion. It is considered a treatment effect due to tumor cell necrosis and subsequent edema formation and increased vascular permeability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF34AFA7-30AC-6D2E-E040-BB89AD4364C0","latestVersionIndicator":"Yes","beginDate":"2011-10-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-13","modifiedBy":"SOKKERL","dateModified":"2023-09-07","changeDescription":"Added concept annotation. mc 4/11/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AE2-75F8-E053-731AD00A4F34","beginDate":"2019-08-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"WORSENED","valueDescription":"Worse","ValueMeaning":{"publicId":"2567097","version":"1","preferredName":"Worse","longName":"2567097","preferredDefinition":"In an declined condition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Worse","conceptCode":"C71686","definition":"In an declined condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D326-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-10-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-10-01","modifiedBy":"MMADDINENI","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AE3-75F8-E053-731AD00A4F34","beginDate":"2019-08-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"STABLE","valueDescription":"Stable","ValueMeaning":{"publicId":"2570725","version":"1","preferredName":"Stable","longName":"2570725","preferredDefinition":"Stable; subject to little fluctuation; showing little if any change.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable","conceptCode":"C30103","definition":"Subject to little fluctuation; showing little if any change.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E152-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"REEVESD","dateModified":"2011-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AE4-75F8-E053-731AD00A4F34","beginDate":"2019-08-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"DECREASED","valueDescription":"Reduced","ValueMeaning":{"publicId":"3135563","version":"1","preferredName":"Reduced","longName":"3135563","preferredDefinition":"Made less in size or amount or degree.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reduced","conceptCode":"C25640","definition":"Made less in size or amount or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FD60D3C-9B64-A345-E040-BB89AD430D6D","latestVersionIndicator":"Yes","beginDate":"2010-09-09","endDate":null,"createdBy":"SORENSENS","dateCreated":"2010-09-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Changed concept definition to match current NCIt. mc 4/13/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AE5-75F8-E053-731AD00A4F34","beginDate":"2019-08-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"INCREASED","valueDescription":"Increase","ValueMeaning":{"publicId":"4592292","version":"1","preferredName":"Increase","longName":"4592292","preferredDefinition":"A process of becoming larger, more numerous, more important, or more likely.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Increase","conceptCode":"C25533","definition":"A process of becoming larger, more numerous, more important, or more likely.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"07C45DB0-A7E4-F70B-E050-BB89AD432ABC","latestVersionIndicator":"Yes","beginDate":"2014-11-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AE6-75F8-E053-731AD00A4F34","beginDate":"2019-08-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"nPR","valueDescription":"Nodular Partial Remission","ValueMeaning":{"publicId":"2724515","version":"1","preferredName":"Nodular Partial Remission","longName":"2724515","preferredDefinition":"Remission with persistent lymphoid nodules in the bone marrow","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodular Partial Remission","conceptCode":"C70633","definition":"Remission with persistent lymphoid nodules in the bone marrow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4450D85F-4EF5-43BF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-01-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40D8903-7AE7-75F8-E053-731AD00A4F34","beginDate":"2020-04-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"ONEDATA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"NEGATIVE","valueDescription":null,"ValueMeaning":{"publicId":"3121428","version":"1","preferredName":"NA Negative","longName":"3121428","preferredDefinition":"A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negative Finding","conceptCode":"C38757","definition":"A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B5A001E-0FEB-AC3B-E040-BB89AD433129","latestVersionIndicator":"Yes","beginDate":"2010-07-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Added concepts for UPMC project per request by U.Reddy. mc 2/25/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40DB2F3-D265-7F9B-E053-731AD00AEDDA","beginDate":"2023-02-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"POSITIVE","valueDescription":null,"ValueMeaning":{"publicId":"5042698","version":"1","preferredName":"Positive Finding","longName":"5042698","preferredDefinition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Positive Finding","conceptCode":"C38758","definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"23BCDB4E-8EE7-8E8D-E050-BB89AD432DF3","latestVersionIndicator":"Yes","beginDate":"2015-11-04","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2015-11-04","modifiedBy":"KUMMEROA","dateModified":"2024-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40DB2F3-D266-7F9B-E053-731AD00AEDDA","beginDate":"2023-02-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"INDETERMINATE","valueDescription":null,"ValueMeaning":{"publicId":"5612326","version":"1","preferredName":"Indeterminate","longName":"5612326","preferredDefinition":"Cannot distinguish between two or more possible values in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indeterminate","conceptCode":"C48658","definition":"Cannot distinguish between two or more possible values in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4533FADE-5652-7B40-E053-F662850A3056","latestVersionIndicator":"Yes","beginDate":"2017-01-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-01-03","modifiedBy":"KUMMEROA","dateModified":"2022-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F40DB2F3-D267-7F9B-E053-731AD00AEDDA","beginDate":"2023-02-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-06","deletedIndicator":"No"},{"value":"CLINICAL RELAPSE","valueDescription":null,"ValueMeaning":{"publicId":"12920266","version":"1","preferredName":"Clinical Relapse","longName":"12920266v1.00","preferredDefinition":"The return of a disease after a period of remission, as determined by clinical signs and symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Relapse","conceptCode":"C191345","definition":"The return of a disease after a period of remission, as determined by clinical signs and symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F54E7A48-D964-0318-E053-731AD00A3D30","latestVersionIndicator":"Yes","beginDate":"2023-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-22","modifiedBy":"KUMMEROA","dateModified":"2023-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F54E7A48-D965-0318-E053-731AD00A3D30","beginDate":"2023-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-22","modifiedBy":"KUMMEROA","dateModified":"2023-02-22","deletedIndicator":"No"},{"value":"irPR","valueDescription":null,"ValueMeaning":{"publicId":"6001373","version":"1","preferredName":"irPR","longName":"6001373","preferredDefinition":"A decrease of greater than or equal to 30% in TMTB relative to baseline, non-target lesions are irNN, and no unequivocal progression of new non-measurable lesions","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"irRECIST Partial Response","conceptCode":"C140315","definition":"A decrease of 30% or more in TMTB relative to baseline, non-target lesions are irNN, and no unequivocal progression of new non-measurable lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B46FAD0-75ED-3F97-E053-F662850A260F","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"KUMMEROA","dateModified":"2022-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00B53FE4-B017-3DC4-E063-731AD00A6F5F","beginDate":"2023-07-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-17","modifiedBy":"KUMMEROA","dateModified":"2023-07-17","deletedIndicator":"No"},{"value":"irCR","valueDescription":null,"ValueMeaning":{"publicId":"6001372","version":"1","preferredName":"irCR","longName":"6001372","preferredDefinition":"A complete disappearance of  all measurable and non-measurable lesions. Lymph nodes must decrease to less than 10 mm in short axis. Confirmation of response is not mandatory.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"irRECIST Complete Response","conceptCode":"C140316","definition":"A complete disappearance of all measurable and non-measurable lesions. Lymph nodes must decrease to < 10 mm in short axis. Confirmation of response is not mandatory.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B46FAD0-75C8-3F97-E053-F662850A260F","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"KUMMEROA","dateModified":"2022-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00B53FE4-B018-3DC4-E063-731AD00A6F5F","beginDate":"2023-07-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-17","modifiedBy":"KUMMEROA","dateModified":"2023-07-17","deletedIndicator":"No"},{"value":"irSD","valueDescription":null,"ValueMeaning":{"publicId":"6001375","version":"1","preferredName":"irSD","longName":"6001375","preferredDefinition":"A failure to meet criteria for irCR or irPR in the absence of irPD.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"irRECIST Stable Disease","conceptCode":"C140317","definition":"A failure to meet criteria for irCR or irPR in the absence of irPD.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B46FAD0-7637-3F97-E053-F662850A260F","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"KUMMEROA","dateModified":"2022-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00B53FE4-B019-3DC4-E063-731AD00A6F5F","beginDate":"2023-07-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-17","modifiedBy":"KUMMEROA","dateModified":"2023-07-17","deletedIndicator":"No"},{"value":"irPD","valueDescription":null,"ValueMeaning":{"publicId":"6001374","version":"1","preferredName":"irPD","longName":"6001374","preferredDefinition":"A minimum 20% increase and minimum 5 mm absolute increase in total measured tumor burden compared to nadir, or irPD for non-target or new non-measurable lesions. Confirmation of progression is recommended minimum 4 weeks after the first irPD assessment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"irRECIST Progressive Disease","conceptCode":"C140319","definition":"A minimum 20% increase and minimum 5 mm absolute increase in total measured tumor burden compared to nadir, or irPD for non-target or new non-measurable lesions. Confirmation of progression is recommended minimum 4 weeks after the first irPD assessment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B46FAD0-7612-3F97-E053-F662850A260F","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"KUMMEROA","dateModified":"2022-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00B53FE4-B01A-3DC4-E063-731AD00A6F5F","beginDate":"2023-07-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-17","modifiedBy":"KUMMEROA","dateModified":"2023-07-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6674535","version":"1","preferredName":"CDISC SDTM Tumor Response Result Terminology Outcome","preferredDefinition":"Terminology associated with the tumor response result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).:The result of an action.","longName":"C96785:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CDISC SDTM Tumor Response Result Terminology","conceptCode":"C96785","definition":"Terminology associated with the tumor response result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83E8FF08-DF52-1D09-E053-F662850ACD4A","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"F40D8909-B57B-75F4-E053-731AD00A1715","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-07-17","changeDescription":"2020-10-8 ak Versioned for removal of CT term. Updated to CT Package 43 release.","administrativeNotes":"2023.7.17 Updated to CT Package 54 release. ak 2023.6.5 Released per WZ review. ak 2023.2.6 Created new version to reflect CT Pkg 52 updates. Ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"7434158","version":"1","longName":"CTEP CDISC Harmonization","context":"CTEP","ClassificationSchemeItems":[{"publicId":"7590138","version":"1","longName":"CTEP CDISC Response","context":"CTEP"}]}],"AlternateNames":[{"name":"RS_RSORRES_LYMPRESP","type":"CTEP CDISC CDE","context":"CTEP"}],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was the lymphocyte response?","url":null,"context":"CTEP"},{"name":"Lymphocyte response","type":"Alternate Question Text","description":"Lymphocyte response","url":null,"context":"CTEP"},{"name":"CTEP Text 1","type":"Alternate Question Text","description":"What was the lymphocytic disease response?","url":null,"context":"CTEP"},{"name":"CTEP Text 2","type":"Alternate Question Text","description":"Lymphocytic disease response","url":null,"context":"CTEP"}],"origin":"CTEP CDISC Harmonization","workflowStatus":"DRAFT NEW","registrationStatus":"Qualified","id":"BD55DDA6-DB43-3553-E053-4EBD850AAB8D","latestVersionIndicator":"Yes","beginDate":"2021-03-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2021-03-12","modifiedBy":"KUMMEROA","dateModified":"2023-02-06","changeDescription":"Created for CTEP CDE Harmonization Response CRF. mc 3.12.2021","administrativeNotes":"2023.2.6 Updated to VD 1.2 to reflect CT Pkg 52 updates. ak 10/21/22 added 1 alt name, 2 AQTs, 1 classification for the CTEP CDISC Harmonization project;","unresolvedIssues":null,"deletedIndicator":"No"}}